Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy

Trial Profile

Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 15 Dec 2015 Status changed from not yet recruiting to recruiting as reported by University hospital Medical Information Network-Japan record.
    • 15 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top